BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND CDKN1B, CDKN4, 1027, ENSG00000111276, MEN4, P27KIP1, P46527, MEN1B, KIP1 AND Treatment
46 results:

  • 1. Pituitary Tumorigenesis-Implications for Management.
    Vamvoukaki R; Chrysoulaki M; Betsi G; Xekouki P
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109772
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
    Tong F; Zhao JX; Fang ZY; Cui XT; Su DY; Liu X; Zhou JH; Wang GX; Qiu ZJ; Liu SZ; Fu JQ; Kang CS; Wang JC; Wang QX
    Pharmacol Res; 2023 Jan; 187():106606. PubMed ID: 36516884
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.
    Oliveira HA; Bueno AC; Pugliesi RS; da Silva Júnior RMP; de Castro M; Martins CS
    J Endocrinol Invest; 2022 May; 45(5):999-1009. PubMed ID: 34988938
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Achalasia and acromegaly: Co-incidence of these diseases or a new syndrome?
    Dolina J; Kunovsky L; Kroupa R; Stary K; Jabandziev P; Nesporova T; Maca K; Andrasina T; Marek F; Kala Z; Vaculova J; Said D; Zapletalova M; Lochman J; Palova Noskova H; Slaby O; Izakovicova Holla L; Borilova Linhartova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):228-235. PubMed ID: 34282806
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Depression among adult patients with primary brain tumour: a cross-sectional study of risk factors in a low-middle-income country.
    Pidani AS; Siddiqui AR; Azam I; Shamim MS; Jabbar AA; Khan S
    BMJ Open; 2020 Sep; 10(9):e032748. PubMed ID: 32912937
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. AKT/GSK-3β/β-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation.
    Tang Z; Yang G; Wang X; Chen F; Liao Z; Zhang Z; Liu Z; Zeng W; Fang M; Wang W; Sun X; Huo G
    J Neurooncol; 2020 Sep; 149(2):231-242. PubMed ID: 32909117
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Somatic and germline mutations in the pathogenesis of pituitary adenomas.
    Vandeva S; Daly AF; Petrossians P; Zacharieva S; Beckers A
    Eur J Endocrinol; 2019 Dec; 181(6):R235-R254. PubMed ID: 31658440
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genetics of Pituitary Tumours.
    Loughrey PB; Korbonits M
    Exp Suppl; 2019; 111():171-211. PubMed ID: 31588533
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.
    Frederiksen A; Rossing M; Hermann P; Ejersted C; Thakker RV; Frost M
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3637-3646. PubMed ID: 30990521
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
    Yu L; Xu J; Liu J; Zhang H; Sun C; Wang Q; Shi C; Zhou X; Hua D; Luo W; Bian X; Yu S
    Neuro Oncol; 2019 Jun; 21(6):742-754. PubMed ID: 30753603
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Inactivation of Citron Kinase Inhibits Medulloblastoma Progression by Inducing Apoptosis and Cell Senescence.
    Pallavicini G; Sgrò F; Garello F; Falcone M; Bitonto V; Berto GE; Bianchi FT; Gai M; Chiotto AMA; Filippi M; Cutrin JC; Ala U; Terreno E; Turco E; Cunto FD
    Cancer Res; 2018 Aug; 78(16):4599-4612. PubMed ID: 29921697
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies].
    Drbalová K; Herdová K; Krejčí P; Nývltová M; Solař S; Vedralová L; Záruba P; Netuka D; Bavor P
    Vnitr Lek; 2016; 62(9 Suppl 3):140-149. PubMed ID: 27734708
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. N-acetylaspartate (NAA) induces neuronal differentiation of SH-SY5Y neuroblastoma cell line and sensitizes it to chemotherapeutic agents.
    Mazzoccoli C; Ruggieri V; Tataranni T; Agriesti F; Laurenzana I; Fratello A; Capitanio N; Piccoli C
    Oncotarget; 2016 May; 7(18):26235-46. PubMed ID: 27036033
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.
    Waye S; Naeem A; Choudhry MU; Parasido E; Tricoli L; Sivakumar A; Mikhaiel JP; Yenugonda V; Rodriguez OC; Karam SD; Rood BR; Avantaggiati ML; Albanese C
    Aging (Albany NY); 2015 Oct; 7(10):854-68. PubMed ID: 26540407
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
    Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
    Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221.
    Brognara E; Fabbri E; Bazzoli E; Montagner G; Ghimenton C; Eccher A; Cantù C; Manicardi A; Bianchi N; Finotti A; Breveglieri G; Borgatti M; Corradini R; Bezzerri V; Cabrini G; Gambari R
    J Neurooncol; 2014 May; 118(1):19-28. PubMed ID: 24595467
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Regulation of the cancer cell membrane lipid composition by NaCHOleate: effects on cell signaling and therapeutical relevance in glioma.
    Lladó V; López DJ; Ibarguren M; Alonso M; Soriano JB; Escribá PV; Busquets X
    Biochim Biophys Acta; 2014 Jun; 1838(6):1619-27. PubMed ID: 24525074
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application.
    van der Merwe N; Bouwens CS; Pienaar R; van der Merwe L; Yako YY; Geiger DH; Kotze MJ
    Metab Brain Dis; 2012 Sep; 27(3):319-26. PubMed ID: 22638694
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
    Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R
    Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.